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Summary
Purpose—Men with epilepsy often have sexual or reproductive abnormalities that are attributed to
alterations in androgen levels, including subnormal free testosterone. Levels of the major metabolites
of testosterone – androsterone (5α-androstan-3α-ol-17-one; 5α, 3α-A), a neurosteroid that acts as a
positive allosteric modulator of GABAA receptors, and its 5β-epimer etiocholanolone (5β-
androstan-3α-ol-17-one; 5β, 3α-A) – may also be reduced in epilepsy. 5α 3α-A has been found in
adult brain and both metabolites, which can also be derived from androstenedione, are present in
substantial quantities in serum along with their glucuronide and sulfate conjugates. This study sought
to determine whether these endogenous steroid metabolites can protect against seizures.
Methods—The anticonvulsant activity of 5α 3α-A and 5β, 3α-A was investigated in electrical and
chemoconvulsant seizure models in mice. The steroids were also examined for activity against
extracellularly-recorded epileptiform discharges in the CA3 region of the rat hippocampal slice
induced by perfusion with 55 μM 4-aminopyridine (4-AP).
Results—Intraperitoneal injection of 5α, 3α-A protected mice in a dose-dependent fashion from
seizures in the following models (ED50, dose in mg/kg protecting 50% of animals): 6 Hz electrical
stimulation (29.1), pentylenetetrazol (43.5), pilocarpine (105), 4-AP (215), and maximal
electroshock (224). 5β, 3α-A was also active in the 6 Hz and pentylenetetrazol models, but was less
potent (ED50 values, 76.9 and 139 mg/kg, respectively), whereas epiandrosterone (5α,3β-A) was
inactive (ED50, ≤300 mg/kg). 5α, 3α-A (10–100 μM) also inhibited epileptiform discharges in a
concentration-dependent fashion in the in vitro slice model, whereas 5β, 3α-A was active but of lower
potency and 5α, 3β-A was inactive.
Conclusions—5α, 3α-A and 5β, 3α-A have anticonvulsant properties. Although of low potency,
the steroids are present in high abundance and could represent endogenous modulators of seizure
susceptibility.
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Male sex steroid hormones (“androgens”) were recognized in the early part of the last century
(1). Androsterone (5α-androstan-3α-ol-17-one; 5α,3α-A), the first androgen to be identified,
was isolated from urine in 1931 and chemically synthesized four years later at the same time
as the first synthesis of testosterone (2). 5α,3α-A and its 5β-epimer etiocholanolone (5β,3α-A)
are the major excreted metabolites of testosterone (3–5). The first step in testosterone
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metabolism is its irreversible reduction by 5α-reductase isoenzymes, which leads to the
formation of the biologically potent androgen 5α-dihydrotestosterone (Fig. 1). Testosterone is
also a good substrate for liver 5β-reductase (6), which synthesizes 5β-dihydrotestosterone. The
reductions at the 5-position are followed by sequential 3α- and 17β-reductions resulting in the
synthesis of 5α,3α-A and 5β,3α-A. The latter two reactions are catalyzed by 3α-hydroxysteroid
dehydrogenase (3α-HSD) and 17β-hydroxysteroid dehydrogenase (17β-HSD), respectively
(Fig. 1). 5α,3α-A and 5β,3α-A can also be derived from the metabolism of androstenedione
through 5α- and 5β-reduction, followed by the action of 3α-HSD. Substantial quantities of both
compounds (~3–4 mg/24 h in young men) are excreted in the urine as 3-glucuronide and 3-
sulfate conjugates (7–10).
5α,3α-A has an identical reduced A-ring as the neurosteroids allopregnanolone (5α,3α-P) and
allotetrahydrodeoxycorticosterone (5α,3α-THDOC), which are potent positive allosteric
modulators of GABAA receptors (11,12). 5β,3α-A is analogous to pregnanolone (5β,3α-P) and
tetrahydrodeoxycorticosterone (5β,3α-THDOC), which also have activity at GABAA
receptors, but are less potent (11,13). In fact, 5α,3α-A has been reported to interact with
GABAA receptors in vitro in a fashion similar to other neurosteroid positive GABAA receptor
modulators. Thus, 5α,3α-A enhances muscimol and flunitrazepam binding and inhibits t-butyl
bicyclophosphorothionate binding in rat brain membranes, and also enhances muscimol-
stimulated 36Cl− flux in intact neurons (14,15). Furthermore, in electrophysiological studies,
5α,3α-A potentiates GABAA receptor chloride currents (15–19). Neurosteroids, including 5α,
3α-P and 5α,3α-THDOC and their 5β-epimers, that act as similar positive GABAA receptor
modulators, have anticonvulsant properties in animal models (11,12,20–23) and recently we
have demonstrated that they also protect against epileptiform activity in an in vitro brain slice
system (24). Consequently, 5α,3α-A and 5β,3α-A could potentially have anticonvulsant
properties although as far as we are aware this has only previously been demonstrated for 5α,
3α-A in regard to ruthenium red convulsions in cats (25) and 3-mercaptoprionic acid seizures
in Syrian hamsters (26).
There is accumulating evidence that neurosteroids with GABAA receptor modulating activity
serve as endogenous regulators of seizure susceptibility (27). Men with temporal lobe epilepsy
often have impaired sexual function, including diminished testicular efficiency and loss of
libido in association with reduced androgen levels (28,29). The deficiency of androgens is
attributed to the effects of antiepileptic medications and also to the suppression of the
hypothalamic-pituitary-gonadal axis by recurrent seizures (30–32). If androgen metabolites
have anti-seizure properties, alterations in androgen levels caused by antiepileptic drugs or
inadequately controlled seizures could be relevant to seizure control. In fact, there is evidence
that long-term antiepileptic drug therapy is associated with markedly reduced urinary excretion
of both 5α,3α-A and 5β,3α-A (3,33). In the present study we characterize for the first time the
anticonvulsant profile of these steroids in several animal seizure models and also in an in vitro
slice model previously shown to be sensitive to neurosteroids (24). For comparison, we
examined the activity 5α,3β-A (epiandrosterone) which is predicted to have very weak activity
at GABAA receptors (11). Our results indicate that the 3α-epimers are effective anticonvulsants
and the structure-activity comparisons indicate that this likely occurs through positive
modulation of GABAA receptors.
MATERIALS AND METHODS
In Vivo Studies
Animals—Male NIH Swiss mice (25–30 g) were housed five per cage and Sprague-Dawley
rats (120–180 g) (Taconic Farms, Germantown, NY) were housed two per cage. Animals were
kept in a vivarium under controlled laboratory conditions (temperature 22–26 °C, humidity
40–50%) with an artificial 12 h light/dark cycle and free access to food and water. Animals
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were allowed to acclimate to the vivarium for at least 5 days. For in vivo testing, the
experimental groups consisted of 6–8 animals. The experiments were performed during the
light phase of the light/dark cycle after at least a 30 min period of acclimation to the
experimental room. Animals were maintained in facilities fully accredited by the Association
for Assessment and Accreditation of Laboratory Animal Care and were performed under
protocols approved by the Animal Care and Use Committee of the National Institute of
Neurological Disorders and Stroke (NINDS) in strict compliance with the Guide for the Care
and Use of Laboratory Animals of the National Research Council (National Academy Press,
Washington, DC; http://www.nap.edu/readingroom/books/labrats/).
Test Substances and Drug Administration—Solutions of 5α,3α-A, 5β,3α-A, 5α,3β-A
and 5α,3α-A D-glucuronide (Sigma-Aldrich, St. Louis, MO) were made fresh daily in 40%
hydroxypropyl-β-cyclodextrin (Trappsol, Cyclodextrin Technologies Development, High
Springs, FL) in sterile 0.9% saline. Further dilutions were made using sterile saline. The
convulsant agents pentylenetetrazol (PTZ), 4-aminopyridine (4-AP) and pilocarpine were
purchased from Sigma-Aldrich and were dissolved in saline immediately before use. All drug
solutions were administered in a volume equaling 0.01 ml/kg. In the PTZ test and the 6 Hz
model, the steroids or vehicle were administered intraperitoneally 15 min before PTZ or
electrical stimulation. The pretreatment interval was based on the time of maximal effect in
the time-course experiment in the 6 Hz model (Fig. 2). Pilot experiments indicated that 5α,
3α-A was most effective against pilocarpine- and 4-AP-induced seizures with a 5 min
pretreatment time. Vehicle alone did not affect seizures in any of the models.
6 Hz Seizure Test—Testing was carried out as previously described (23). In brief, 3-s corneal
stimulation (200 μs-duration, 32-mA monopolar rectangular pulses at 6 Hz) was delivered by
a constant current device (ECT Unit 5780, Ugo Basile, Comerio, Italy). Ocular anesthetic (0.5%
tetracaine) was applied to the corneas 15 min before stimulation. Immediately before
stimulation, the corneal electrodes were wetted with saline to provide good electrical contact.
Following the stimulation the animals exhibited a “stunned” posture associated with rearing
and automatic movements that lasted from 60 to 120 s in untreated animals. Animals resumed
their normal exploratory behavior after the seizure. The experimental endpoint was protection
against the seizure: an animal was considered to be protected if it resumed its normal
exploratory behavior within 10 s of stimulation.
Pentylenetetrazol (PTZ) Seizure Test—Testing was carried out as previously described
(11). In brief, mice were injected subcutaneously with PTZ (80 mg/kg) and were observed for
a 30-min period. Mice failing to show clonic seizures lasting longer than 5 s were scored as
protected.
Maximal Electroshock (MES) Seizure Test—Animals were subjected to a 0.2 s, 60-Hz
electrical stimulus through corneal electrodes (as described above). The electroshock unit was
adjusted to deliver a constant current of 50 mA. Animals failing to show tonic hindlimb
extension were scored as protected (11).
4-Aminopyridine (4-AP) Seizure Test—Testing was carried out as previously described
(34). Mice were injected subcutaneously with a CD97 dose (13.3 mg/kg) of 4-AP. The animals
exhibited signs of behavioral activation progressing to clonic and tonic seizures. Animals
failing to exhibit tonic hindlimb extension were scored as protected.
Pilocarpine Seizure Test—Testing was carried out as previously described (21). Mice were
injected intraperitoneally with 1 mg/kg scopolamine methyl bromide to prevent the peripheral
cholinergic activation. A few minutes later, seizures were induced by subcutaneous injection
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of a CD97 dose (dose producing seizures in 97% of animals) of pilocarpine (416 mg/kg).
Animals were observed for 2 h after the pilocarpine injection. All control mice had severe
generalized clonic seizures followed within 45 min by death. Mice failing to show generalized
clonic seizures lasting longer than 10 s were scored as protected. The latencies to generalized
clonic seizures and death were also recorded.
Motor Toxicity Test—Steroids were evaluated for motor toxicity using a modification of
the horizontal screen test as previously described (11). Mice were placed on a horizontally
oriented grid (consisting of parallel 1.5-mm diameter rods situated 1 cm apart) and the grid
was inverted. Animals that fell from the grid within 10 s were scored as impaired.
Data Analysis—To construct dose-response curves, steroids were tested at several doses
spanning the dose producing 50% protection (ED50) or motor impairment (TD50). At least 6–
8 mice were tested at each dose. ED50 and TD50 values and their corresponding 95% confidence
limits were determined by log-probit analysis using the Litchfield and Wilcoxon method
(PHARM/PCS Version 4.2, MicroComputer Specialists, Philadelphia, PA). The protective
index (PI), a measure of relative toxicity, was taken as the ratio TD50/ED50. The mean latency
to seizure values in the pilocarpine model was compared by one-way analysis of variance (one-
way ANOVA). Comparisons of the mean time to seizure onset values with control were made
with the Dunnett’s t-test. Comparisons of the percent lethality with control were made with
the Fisher’s exact test.
In Vitro Studies
4-AP-Induced Epileptiform Activity in the Hippocampal Slice—Rats were
decapitated under brief carbon dioxide narcosis. The brains were rapidly removed and
immediately submerged in an ice-cold cutting solution. Transverse hippocampal slices (500
μm thick) were prepared with a Vibratome (Technical Products International, INC., St. Louis,
MO) and equilibrated before recording for at least 1 h in artificial cerebrospinal fluid (ACSF)
bubbled with carbogen gas (95% O2/5% CO2) at 32–33 °C. The composition of the ACSF (in
mM) was: 130 NaCl; 26 NaHCO3; 3 KCl; 1.25 NaH2PO4; 2 CaCl2; 1 MgCl2; 10 D-glucose,
pH 7.4. The cutting solution was similar to ACSF except that NaCl was replaced with isosmotic
sucrose. After equilibration, the slices were transferred to an interface-type recording chamber
that was continuously gravity-perfused during the 1 h of the experiment with warmed (33 °C)
ACSF at a flow rate of 2.5–3 ml/min. The surface of the slice was exposed to a gentle stream
of humidified carbogen gas. Extracellular field recordings were carried out in the CA3
pyramidal layer with glass micropipettes (2–10 M) filled with ACSF. The location of the
recording electrode was optimized by maximizing the field potential amplitude evoked in
response to a 100-ms test stimulus applied to the dentate gyrus mossy fibers. The amplified
electrode signals (DAM-80, World Precision Instruments, Sarasota, FL) were digitized
(Digidata 1322A) and acquired by pClamp 9.0 software (both from Axon Instruments, Union
City, CA). Events were detected and counted off-line with Mini Analysis Program
(Synaptosoft, Decatur, GA). The parameters were empirically set to detect a maximum number
of population responses that were clearly discernible from the background noise. The amplitude
threshold was always ±0.2 mV, which is 10-fold greater than the typical background noise
level of 0.02 mV. The event rate during the course of each experiment is expressed by plotting
the frequency of events in successive 10-min intervals against the time of the recording. To
evoke spontaneous epileptiform discharges, the slice perfusion solution was changed from
ACSF to ACSF supplemented with 55 μM 4-AP. The 4-AP solution also contained various
concentrations of the test steroids (10–300 μM) or vehicle (0.2–0.3% 2-hydroxypropyl-β-
cyclodextrin). The vehicle at these concentrations had no apparent effect on the epileptiform
discharges.
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Data Analysis—The effects of 5α,3α-A or its epimers on 4-AP-induced epileptiform activity
in the hippocampal slice were compared by two-way analysis of variance with repeated
measures (two-way ANOVA). Specific comparisons between the treatments were made by a
post-hoc multiple comparisons procedure (Bonferroni t-test).
RESULTS
In Vivo Mouse Seizure Models
6 Hz Model—We first sought to determine whether 5α,3α-A is protective in the 6 Hz electrical
stimulation-induced seizure model like other neurosteroids that act as positive modulators of
GABAA receptors (23) and, if so, determine the time course of the effect. As shown in Fig. 2,
5α,3α-A at a dose of 100 mg/kg did protect mice against 6 Hz seizures and showed a maximal
effect 15 min after injection; by 2 h, only minimal protective activity was evident. We next
examined the dose-dependence for protection in this model in experiments with a 15 min
interval between 5α,3α-A injection and testing. At doses of 10 to 100 mg/kg, 5α,3α-A exhibited
dose-dependent protective activity (Fig. 3A); the ED50 value determined from the dose-effect
relationship is presented in Table 1. 5β,3α-A was also protective in the 6 Hz model, but was
less potent than 5α,3α-A, whereas 5α,3β-A was inactive at a dose of 300 mg/kg. 5α,3α-A
glucuronide was also inactive in the 6 Hz model at a dose of 300 mg/kg when injected either
30 or 60 min before testing (3 mice each group).
PTZ-Induced Seizures—5α,3α-A (10–100 mg/kg) conferred dose-dependent protection in
the PTZ model (Fig. 3B; Table 1). The 5β,3α-A epimer had approximately 3-fold lower potency
and 5α,3β-A was inactive at a dose of 300 mg/kg.
MES Test—5α,3α-A at higher doses (150–300 mg/kg) exhibited dose-dependent activity in
the mouse MES test with nearly complete protection conferred at 300 mg/kg (Fig. 4; Table 1).
The 5α,3β-A epimer was inactive at 300 mg/kg (data not shown).
4-AP-Induced Seizures—5α,3α-A conferred protection against tonic hindlimb extension
elicited by s.c. injection of 4-AP at doses comparable to those that were effective in the MES
test (150–300 mg/kg) (Fig. 4; Table 1).
Pilocarpine-induced Status Epilepticus—As illustrated in Fig. 5, pretreatment with the
5α,3α-A (50–300 mg/kg) conferred dose-dependent protection against pilocarpine-induced
limbic motor seizures (Table 1). 5α,3α-A pretreatment significantly increased the latency to
seizure onset as well as the survival rate in a dose-dependent fashion.
Motor Toxicity—5α,3α-A at doses substantially higher than those that were protective in the
6 Hz and PTZ models caused motor impairment as assessed by the horizontal screen test. The
TD50 value was 152 mg/kg (Table 1). 5β,3α-A also caused motor impairment at higher doses
(150–300 mg/kg) but only 4 of 5 animals were affected even at the 300 mg/kg dose. 5α,3β-A
did not affect motor performance at a dose of 300 mg/kg. The ratios between the protective
doses in the seizure models (ED50 values) and the TD50 values for motor toxicity are given in
Table 1.
In Vitro Hippocampal Slice Model
Perfusion of hippocampal slices with 55 μM 4-AP elicited positive going discharges in the
CA3 region that increased in frequency from about 30 min−1 to nearly 60 min−1 at the end of
the 60 min experimental period (F5,179 = 11.0; p < 0.001) (Fig. 6A). Coperfusion of 5α,3α-A
with 4-AP (10–100 μM) resulted in a concentration-dependent reduction in the number of
epileptiform discharges at each time point (F3,179 = 18.5; p < 0.001) (Fig. 6A). In addition,
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there was a significant interaction between treatment and time in slices treated with 5α,3α-A
(F15,179 = 3.4; p < 0.001). Thus, for 50 and 100 μM 5α,3α-A there was a progressive reduction
in discharge frequency after the 20 min epoch whereas in control recordings the frequency
showed a monotonic increase over the 60 min recording. At 100 μM, 5α,3α-A almost
completely eliminated the discharges.
Coperfusion with 100 μM 5β,3α-A also reduced the discharge frequency at all time points (Fig.
6B) but the magnitude of the effect was substantially less than for 5α,3α-A. Two-way ANOVA
revealed a significant time effect for 100 μM 5β,3α-A (F5,107 = 21.3; p < 0.001) and also a
significant treatment effect (F1,107 = 5.4; p < 0.05), but no treatment vs. time effect (F5,107 =
0.23; p > 0.05) (Fig. 6B). Individual time points for 5β,3α-A were only significantly different
from vehicle at 30 and 60 min (Fig. 6B). Higher concentrations of 5β,3α-A were not tested due
to limitations of solubility. Perfusion with 5α,3β-A did not significantly affect the discharge
frequency (F5,107 = 0.75; p > 0.05) (Fig. 6C).
DISCUSSION
Men with epilepsy often have altered androgen levels in comparison with control subjects who
do not have epilepsy (28). In particular, serum levels of free testosterone and adrostenedione
are reduced in men with uncontrolled temporal lobe seizures (3,32,35,36). Remarkably, the
androgen levels normalize following epilepsy surgery that results in successful seizure control
(36), suggesting that uncontrolled seizures are responsible for the endocrine abnormalities,
although enzyme-inducing antiepileptic drugs are also likely to play an important role through
effects on sex hormone binding globulin (30,32). Whatever the cause, subnormal serum free
testosterone and androstenedione would be expected to result in reduced production of the
metabolites 5α,3α-A and 5β,3α-A. In fact, men with epilepsy receiving treatment with
antiepileptic medications excrete diminished quantities of 5α,3α-A and 5β,3α-A in comparison
with age-matched control subjects (3,33).
In the present study, we have found that 5α,3α-A is an effective anticonvulsant in several
seizure models. Similarly, 5β,3α-A has anticonvulsant properties but is less potent, as is
consistent with the usual structure-activity relationship for GABAA receptor modulatory
activity of A-ring reduced neurosteroids (27). The 5α,3β-epimer, which is expected to have
minimal GABAA receptor modulatory activity, was inactive both in vivo and in vitro. Overall,
the structure-activity relationship suggests that the protective activity in the 6 Hz and PTZ
models is due predominantly to effects on GABAA receptors. In fact, various studies have
confirmed that 5α,3α-A is a positive modulator of GABAA receptors (14–19); we would predict
that 5β,3α-A has similar, but weaker activity, although this remains to be demonstrated
experimentally. It is unlikely that the weak androgenic activity of 5α,3α-A contributes to its
anticonvulsant properties since testosterone, which has approximately 10-times greater
androgenic activity (37), is inactive in the seizure models (unpublished observations). Since
5α,3α-A and 5β,3α-A are present in substantial quantities in serum (39–44), cerebrospinal fluid
(45) and brain (46), it seems plausible that they could play a role as endogenous regulators of
seizure susceptibility. Neither steroid was exceptionally potent, although in the 6 Hz and PTZ
models, the potency of 5α,3α-A was only 2- and 3-fold less than that of 5α,3α-P and 5α,3α-
THDOC (11,23), which have been proposed as endogenous regulators of seizure susceptibility
in catamenial epilepsy and stress (27). Nevertheless, the extent to which the potencies are
predictive of activity in human epilepsy is unclear, since in human epilepsy even small
reductions in the excitability of critical brain regions may reduce seizure frequency. Serum
levels of unconjugated 5α,3α-A in men and women are 3–5 nM (40,41,44), which is in the
same range as the concentrations of 5α,3α-P in women in the luteal phase of the menstrual
cycle (47–49), and one study indicated that the amounts of 5α,3α-A may be far higher (45). A
considerable portion of the androsterone epimers may be as the glucouronide (7,44,50–52) and
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sulfate (42,44,53) conjugates. Serum androsterone glucuronide levels are ~15–60-fold greater
than the unconjugated amounts (40,42) and the levels of the sulfate may be >300-fold the
unconjugated form (42,44). Whether the conjugates can serve as sources of the free steroids
for delivery to the brain remains to be determined.
Androgens have previously been implicated in the regulation of seizure activity in men with
epilepsy (54). In particular, the reduced metabolite of testosterone 5α-androstane-3α,17β-diol
(3α-diol; 3α-androstanediol; Fig. 1) has been shown to have anticonvulsant activity and has
been proposed as an endogenous anticonvulsant substance (55,56). However, the body burden
of 5α,3α-A and 5β,3α-A is likely to be substantially greater than that of the 17-OH
intermediates. In men, while the serum free levels of 5α,3α-A modestly exceed those of free
3α-diol (44), the ratio for glucuronide conjugates in serum is about 5-fold (57) and the ratio of
conjugated 5α,3α-A to conjugated 3α-diol in urine is 20 or more (10). Therefore, 5α,3α-A and
possibly 5β,3α-A are even more likely to be relevant in the regulation of seizure susceptibility
in persons with epilepsy. It is noteworthy that women also produce substantial amounts of 5α,
3α-A and 5β,3α-A (9,10,42,57), suggesting that the steroids could also play a role in the
regulation of seizure susceptibility in women.
5α,3α-A had the greatest potency in the 6 Hz and PTZ models, and was of lower potency against
pilocarpine-, 4-AP- and MES-induced seizures. The relative potency ranking in the various in
vivo models is similar to that of other GABAA receptor modulating neurosteroids (11,21,23).
Indeed, we recently reported that such neurosteroids are particularly effective in the 6 Hz model
(23), and this model was most sensitive to 5α,3α-A. In the 6 Hz model, 5α,3α-A had a rapid
time course of action, comparable to that of other similar neurosteroids (11,12).
Although 5α,3α-A has an anticonvulsant profile similar to that of other GABAA receptor
modulating neurosteroids, some differences were noted. At high doses, 5α,3α-A was protective
in the MES and 4-AP seizure models, unlike 5α,3α-P which is inactive at comparable doses
(11). Whether high doses of 5α,3α-A exert pharmacological actions on targets other than
GABAA receptors that account for the activity in these models remains to be determined.
GABAergic agents are not typically active in the 4-AP model in vivo, where seizures occur in
the face of GABA synaptic tone that is strongly enhanced by the release-potentiating action of
4-AP (34). In contrast, GABA potentiating neurosteroids are effective in the in vitro 4-AP
model (24). We have postulated that the in vitro activity may be due to tonic activation of
GABAA receptors, which directly suppresses the firing of principal cells and interneurons
(24). The in vitro activity of 5α,3α-A and 5β,3α-A in the present study presumably occurs
through a similar tonic action.
The protective index (PI) values reported in Table 1 provide a measure of therapeutic potency
in relation to the potency for induction of motor impairment. In the 6 Hz and PTZ models,
5α,3α-A exhibited PI values comparable to or higher than those reported for progesterone and
deoxycorticosterone derivatives (11). This suggests that exogenously administered 5α,3α-A or
related compounds could be of potential utility as therapeutic agents. The PI of the 5β epimer
was substantially less than that of 5α,3α-A, indicating that the 5α-stereoisomer would be
preferred therapeutically. A similar preference for the 5α epimers has been previously reported
for other neurosteroids (11,21).
In conclusion, our results demonstrate that 5α,3α-A and 5β,3α-A are protective in various
seizure models in vivo and in vitro. Both steroids are present endogenously in serum and brain
at concentrations that may exceed those of other neurosteroids. Moreover, there is evidence
that the levels are reduced in some men with epilepsy and could therefore be a cause of
increased seizure susceptibility. Therapeutic strategies seeking to replace the diminished
“neurosteroid tone” in men with epilepsy are worthy of investigation.
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FIG. 1.
Metabolic pathways for conversion of testosterone and androstenedione to androsterone (5α-
androstan-3α-ol-17-one; 5α,3α-A) and etiocholanolone (5β-androstan-3α-ol-17-one; 5β,3α-
A). 5α-Reductase (5α-R) and 5β-reductase (5β-R) catalyze the rate-limiting irreversible initial
steps, which are followed by sequential reductions by 3α-hydroxysteroid dehydrogenase (3α-
HSD) and 17β-hydroxysteroid dehydrogenase (17β-HSD). 5α,3α-A and 5β,3α-A are
conjugated by gucuronidation in the liver. 5α,3α-A has been identified as a substrate for human
dehydroepiandrosterone (DHEA) sulfotransferase and some studies have indicated that 5α,
3α-A sulfate may be more abundant in serum than the glucuronide (44,53).
Kaminski et al. Page 11
Epilepsia. Author manuscript; available in PMC 2005 July 29.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
FIG. 2.
Time course for protection by androsterone (5α,3α-A) at a dose of 100 mg/kg in the 6 Hz
electrical stimulation (32 mA, 3 s) model. The interval between the steroid injection and the
electrical stimulus is plotted on the abscissa and the percentage of animals protected against
seizures is plotted on the ordinate. Each point represents 6 mice.
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FIG. 3.
Dose-response relationships for protective activity of androsterone (5α,3α-A) and its 5β- and
3β-epimers in the 6 Hz electrical stimulation model (A) and the pentylenetetrazol (PTZ) model
(B). Steroids were administered 15 min before electrical stimulation or injection of PTZ (see
Methods). Data points indicate percentage of animals protected. Each point represents 6 to 8
mice.
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FIG. 4.
Dose-response relationships for protection by androsterone (5α,3α-A) in the maximal
electroshock (MES; 50 mA, 0.2 s, 60 Hz) and 4-aminopyridine (4-AP; 13.3 mg/kg, s.c.) models.
5α,3α-A was administered 15 min before electrical stimulation in the MES test and 5 min before
4-AP (see Methods). Data points indicate percentage of animals protected against seizures.
Each point represents 6 to 8 mice.
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FIG. 5.
Dose-response relationships for androsterone (5α,3α-A) in the pilocarpine model. The steroid
was administered 15 min before pilocarpine (416 mg/kg, s.c.). The percentage of animals
protected against seizures at each dose is plotted at the top. The mean ± S.E.M. time to seizure
onset is plotted in the middle bar chart. Steroid treatment significantly increased the latency
(F3,31 = 8.0; p < 0.001). The percent lethality is shown in the lower bar chart. Six to 8 mice
were tested at each dose. *Significantly different from control p < 0.05 (time to seizure onset
by Dunnett’s t-test; percent lethality by Fisher’s exact test).
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FIG. 6.
Effects of androsterone (5α,3α-A) and its 5β and 3β epimers on the frequency of 4-
aminopyridine (55 μM)-induced spontaneous epileptiform discharges in the CA3 region of the
in vitro hippocampal slice. Co-application of various concentrations of 5α,3α-A along with 4-
AP significantly reduced bursting in a concentration dependent fashion (F3,179 = 18.5; p <
0.001; panel A). 5β,3α-A (100 μM) also significantly reduced bursting activity (F1,107 = 5.4;
p < 0.05; panel B), while 5α,3β-A did not have a significant effect (F5,107 = 0.75; p > 0.05;
panel C). Each point represents the mean ± S.E.M. of event frequency values during the
preceding 10 min epoch (6 slices). Frequency values from a common control group collected
throughout the experiments are depicted on all three graphs (12 slices). Concentrations higher
than 100 μM could note be tested due to the limited solubility of the steroids. *p < 0.05 vs.
control group (post-hoc Bonferroni t-test).
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TABLE 1
ED50 values of androsterone (5α,3α-A), etiocholanolone (5β,3α-A) and epiandrosterone (5α,3β-A) for protection
in the 6 Hz electrical stimulation, pentylenetetrazol (PTZ), pilocarpine, 4-aminopyridine (4-AP) and maximal
electroshock (MES) seizure models in mice
Androsterone epimer Seizure model ED50 (mg/kg)
a PIb
5α,3α-A 6 Hz 29.1(16.2–52.1) 5.23
5β,3α-A 6 Hz 76.9 (53.7–109.9) 1.98
5α,3β-A 6 Hz > 300 N.D.
5α,3α-A PTZ 43.5 (31.6–60.0) 3.50
5β,3α-A PTZ 138.7 (110.5–169.8) 1.53
5α,3β-A PTZ > 300 N.D.c
5α,3α-A Pilocarpine 105.4 (47.7–232.7) 1.44
5α,3α-A 4-AP 215.3 (173.8–266.6) 0.70
5α,3α-A MES 223.7 (182.5–274.1) 0.68
a
ED50 values (with 95% confidence intervals) represent the dose in mg/kg that is estimated to protect 50% of animals.
b
PI (protective index) is the ratio between TD50 (the dose estimated to produce motor impairment in 50% of animals) and the ED50. The TD50 value
for 5α,3α-A was 152.3 (133.9–173.1) mg/kg, while the TD50 for its 5β-epimer was 212.3 (150.8–298.7). 5α,3β-A did not cause motor impairment at
doses as high as 300 mg/kg.
c
N.D., not possible to determine.
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